Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 676 to 690 of 2044 results for guidelines

  1. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

    Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.

  2. Dulaglutide for treating type 2 diabetes in children and young people TS ID 10660

      Status ...

  3. Register your organisation as a stakeholder

    Register your organisation as a stakeholder with NICE.

  4. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing venous thromboembolism after total hip or total knee replacement in adults.

  5. How voluntary and community sector (VCS) organisations can help us develop guidance

    Support for organisations who contribute to developing our guidance

  6. Discussing and planning medicines support

    A quick guide for home care managers providing medicines support.

  7. Effective record keeping and ordering of medicines

    A quick guide for home care managers providing medicines support

  8. Person-centred future planning

    A quick guide for practitioners supporting people growing older with learning disabilities.

  9. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development [GID-HST10054] Expected publication date: TBC

  10. Semaglutide for treating type 2 diabetes (ID1450)

    Awaiting development [GID-TA10438] Expected publication date: TBC

  11. Dulaglutide for treating type 2 diabetes [ID1451]

    Awaiting development [GID-TA10439] Expected publication date: TBC

  12. Arranging services for people with a learning disability and behaviour that challenges

    information NICE guideline: Learning disabilities and behaviour that challenges - service design and delivery . NICE...

  13. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (DG5)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver

  14. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

  15. Helping to prevent infection

    Help for care home managers and staff to prevent infection